TrialEuropean urology2021

A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma.

Thomas E Hutson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.